Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Mizushige, Tomoko ^a   Kobori, Hiroyuki ^a   Nishijima, Yoko ^a   Yano, Yuichiro ^b   Sakata, Koji ^c   Hayakawa, Manabu ^d   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALOGLIPTIN; ANGIOTENSINOGEN; CREATININE; HEMOGLOBIN A1C; ALBUMINOID; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; PIPERIDINE DERIVATIVE; URACIL;

ADD ON THERAPY; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE URINE LEVEL; DIABETIC PATIENT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CONCENTRATING CAPACITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN URINE LEVEL; RENAL PROTECTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; JAPAN; KIDNEY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PROGNOSIS; STATISTICAL MODEL; TREATMENT OUTCOME; URINE;

AGED; ALBUMINS; ANGIOTENSINOGEN; BIOMARKERS; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PIPERIDINES; PROGNOSIS; TREATMENT OUTCOME; URACIL;

EID: 84941098388     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/517472     Document Type: Article

References (34)

1. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, "The intrarenal renin-Angiotensin system: from physiology to the pathobiology of hypertension and kidney disease, " Pharmacological Reviews, vol. 59, no. 3, pp. 251-287, 2007
2. H. Kobori, M. Kamiyama, L. M. Harrison-Bernard, and L. G. Navar, "Cardinal role of the intrarenal renin-Angiotensin system in the pathogenesis of diabetic nephropathy, " Journal of Investigative Medicine, vol. 61, no. 2, pp. 256-264, 2013
3. Y. Nagai, L. Yao, H. Kobori et al. , "Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats, " Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 703-711, 2005
4. Y. Suzaki, Y. Ozawa, and H. Kobori, "Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats, " International Journal of Biological Sciences, vol. 3, no. 1, pp. 40-46, 2007
5. K. Miyata, N. Ohashi, Y. Suzaki, A. Katsurada, and H. Kobori, "Sequential activation of the reactive oxygen species/angiotensinogen/renin-Angiotensin system axis in renal injury of type 2 diabetic rats, " Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 8, pp. 922-927, 2008
6. M. Kamiyama, M. Urushihara, T. Morikawa et al. , "Oxidative stress/angiotensinogen/renin-Angiotensin system axis in patients with diabetic nephropathy, " International Journal of Molecular Sciences, vol. 14, no. 11, pp. 23045-23062, 2013
7. W. J. Liu, S. H. Xie, Y. N. Liu et al. , "Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 340, no. 2, pp. 248-255, 2012
8. M. R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso, "Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition, " Diabetes Care, vol. 35, no. 10, pp. 2076-2082, 2012
9. R. Kodera, K. Shikata, H. U. Kataoka et al. , "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes, " Diabetologia, vol. 54, no. 4, pp. 965-978, 2011
10. K. W. Joo, S. Kim, S.-Y. Ahn et al. , "Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney, " BMC Nephrology, vol. 14, no. 1, article 98, 2013
11. K. D. Burns and S. Hiremath, "Urinary angiotensinogen as a biomarker of chronic kidney disease: ready for prime time?" Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3010-3013, 2012
12. A. Nishiyama, Y. Konishi, N. Ohashi et al. , "Urinary angiotensinogen reflects the activity of intrarenal reninangiotensin system in patients with IgA nephropathy, " Nephrology Dialysis Transplantation, vol. 26, no. 1, pp. 170-177, 2011
13. K. T. Mills, H. Kobori, L. L. Hamm et al. , "Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease, " Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3176-3181, 2012
14. H. Kobori and M. Urushihara, "Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease, " Pflugers Archiv European Journal of Physiology, vol. 465, no. 1, pp. 3-12, 2013
15. S. Ogawa, H. Kobori, N. Ohashi et al. , "Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy, " Biomarker Insights, vol. 2009, no. 4, pp. 97-102, 2009
16. T. Saito, M. Urushihara, Y. Kotani, S. Kagami, and H. Kobori, "Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes, " The American Journal of the Medical Sciences, vol. 338, no. 6, pp. 478-480, 2009
17. M. Sawaguchi, S.-I. Araki, H. Kobori et al. , "Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetesmellitus, " Journal of Diabetes Investigation, vol. 3, no. 3, pp. 318-324, 2012
18. S. Matsuo, E. Imai, M. Horio et al. , "Revised equations for estimated GFR from serum creatinine in Japan, " The American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982-992, 2009
19. A. Katsurada, Y. Hagiwara, K. Miyashita et al. , "Novel sandwich ELISA for human angiotensinogen, " American Journal of Physiology: Renal Physiology, vol. 293, no. 3, pp. F956-F960, 2007
20. H. Kobori, L. M. Harrison-Bernard, and L. G. Navar, "Expression of angiotensinogen mRNA and protein in angiotensin IIdependent hypertension, " Journal of the American Society of Nephrology, vol. 12, no. 3, pp. 431-439, 2001
21. N. Yanagawa, A. W. Capparelli, O. D. Jo, A. Friedal, J. D. Barrett, and P. Eggena, "Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture, " Kidney International, vol. 39, no. 5, pp. 938-941, 1991
22. P. P. Leyssac, "Changes in single nephron renin release are mediated by tubular fluid flow rate, " Kidney International, vol. 30, no. 3, pp. 332-339, 1986
23. M. Sibony, J.-M. Gasc, F. Soubrier, F. Alhenc-Gelas, and P. Corvol, "Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme, " Hypertension, vol. 21, no. 6, pp. 827-835, 1993
24. T. Matsusaka, F. Niimura, A. Shimizu et al. , "Liver angiotensinogen is the primary source of renal angiotensin II, " Journal of the American Society ofNephrology, vol. 23, no. 7, pp. 1181-1189, 2012
25. T. Matsusaka, F. Niimura, I. Pastan, A. Shintani, A. Nishiyama, and I. Ichikawa, "Podocyte injury enhances filtration of liverderived angiotensinogen and renal angiotensin II generation, " Kidney International, vol. 85, no. 5, pp. 1068-1077, 2014
26. D. Nakano, H. Kobori, J. L. Burford et al. , "Multiphoton imaging of the glomerular permeability of angiotensinogen, " Journal of the American Society ofNephrology, vol. 23, no. 11, pp. 1847-1856, 2012
27. S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerularmesangial cells, " Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431-2437, 1994
28. T. Yamamoto, T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border, "Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 5, pp. 1814-1818, 1993
29. H. Ha and H. Endou, "Lipid peroxidation in isolated rat nephron segments, " The American Journal of Physiology-Renal Fluid and Electrolyte Physiology, vol. 263, no. 2, pp. F201-F207, 1992
30. H. Ha and H. B. Lee, "Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose, " Kidney International, Supplement, vol. 58, supplement 77, pp. S19-S25, 2000
31. S. Ogawa, M. Matsushima, T. Mori et al. , "Identification of the stages of diabetic nephropathy at which angiotensin II receptor blockers most effectively suppress albuminuria, " American Journal of Hypertension, vol. 26, no. 9, pp. 1064-1069, 2013
32. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al. , "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, " The New England Journal of Medicine, vol. 345, no. 12, pp. 861-869, 2001
33. J. Soltysiak, B. Skowronska, P. Fichna et al. , "Urinary angiotensinogen and urinary sodium are associated with blood pressure in normoalbuminuric children with diabetes, " Pediatric Nephrology, vol. 29, no. 12, pp. 2373-2378, 2014
34. M. Kamiyama, A. Zsombok, and H. Kobori, "Urinary angiotensinogen as a novel early biomarker of intrarenal reninangiotensin system activation in experimental type 1 diabetes, " Journal of Pharmacological Sciences, vol. 119, no. 4, pp. 314-323, 2012.